Modulation of genetic hypertension by short-term AVP V(1a) or V2 receptor antagonism in young SHR

American Journal of Physiology - Renal Physiology

Volumn 272, Issue 2 41-2, 1997, Pages

  Naitoh, Mareo ^a   Burrell, Louise M ^a   Risvanis, John ^a   Aldred, Kathryn L ^a   Rockell, Melinda D ^a   Johnston, Colin I ^a   Phillips, Paddy A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Arginine vasopressin; Blood pressure

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANGIOTENSIN; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MOZAVAPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIURESIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE MASS; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0030868607     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.1997.272.2.f229     Document Type: Article

References (32)

1. Bankir, L., M. Ahloulay, N. Bouby, T. T. M. Trinh, F. Machet, B. Lbcour, and P. Jungers. Is the process of urinary urea concentration responsible for a high glomerular filtration rate? J. Am. Soc. Nephrol. 4: 1091-1103, 1993.
2. Bankir, L., and N. Bouby. Vasopressin and urinary concentration: additional risk factors in the progression of chronic renal failure. Am. J. Kidney Dis. 17, Suppl. 1: 20-26, 1991.
3. Bruner, C. A., J. H. Myers, C. F. Sing, P. T. Jokelainen, and R. C. Webb. Genetic association of hypertension and vascular changes in stroke-prone spontaneously hypertensive rats. Hypertension Dallas 8: 904-910, 1986.
4. Burrell, L. M., P. A. Phillips, J. Risvanis, K. A. Aldred, A.-M. Hutchins, and C. I. Johnston. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension Dallas 26: 828-834, 1995.
5. Burrell, L. M., P. A. Phillips, J. M. Stephenson, J. Risvanis, and C. I. Johnston. Blood pressure-lowering effect of an orally active vasopressin Vl receptor antagonist in mineralocorticoid hypertension in rat. Hypertension Dallas 23: 737-743, 1994.
6. Crofton, J. T., L. Share, and Z. P. Horovitz. The effect of SQ 14255 on systolic blood pressure and urinary excretion of vasopressin in the development of spontaneously hypertensive rat. Hypertension Dallas 1: 462-467, 1979.
7. Datar, S., E. K. Y. Chiu, and J. R. McNeil. Reflexes fail to reduce pressor activity of vasopressin in spontaneous hypertension. Am. J. Physiol. 248 (Heart Circ. Physiol. 17): H49-H59, 1985.
8. Eiken, P., C. Emmeluth, H. J. Schütten, and P. Bie. Vasopressin and angiotensin II in the conscious dog: synergistic effects on renal excretory parameters? Clin. Sci. Lond. 83: 467-475, 1992.
9. Freslon, J. L., and J. F. Giudicelli. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br. J. Pharmacol. 80: 533-543, 1983.
10. Harrap, S. B., and A. E. Doyle. Genetic co-segregation of renal haemodynamics and blood pressure in the spontaneously hypertensive rat. Clin. Sci. Lond. 74: 63-69, 1988.
11. Harrap, S. B., G. A. Mitchell, D. J. Casely, C. Mirakian, and A. E. Doyle. Angiotensin II, sodium and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension Dallas 21: 50-55, 1993.
12. Harrap, S. B., W. M. Van der Merwe, S. A. Griffen, F. Macpherson, and A. F. Lever. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension Dallas 16: 603-614, 1990.
13. 2 receptor. J. Clin. Invest. 84: 418-426, 1989.
14. Johnston, C. I., F. A. O. Mendelsohn, and D. J. Casely. Evaluation of renin and angiotensin assays and their clinical applications. Med. J. Aust. 1: 126-128, 1971.
15. Judy, W. V., A. M. Watanabe, W. R. Murphy, B. S. Aprison, and P. Yu. Sympathetic nerve activity and blood pressure in normotensive backcross rats genetically related to the spontaneously hypertensive rats. Hypertension Dallas 1: 598-604, 1979.
16. Kost, C. K., Jr., P. Li, and E. K. Jackson. Blood pressure after captopril withdrawal from spontaneously hypertensive rats. Hypertension Dallas 25: 82-87, 1995.
17. Li, P., and D. D. Smyth. Decreased renal activity of vasopressin in spontaneously hypertensive rats. J. Hypertens. 11: 41-48, 1993.
18. Liard, J. F. Cardiovascular effects of vasopressin: some recent aspects. J. Cardiovasc. Pharmacol. 8, Suppl. 7: S61-S65, 1986.
19. Loesch, A., A. Tomlinson, and G. Burnstock. Localization of arginine-vasopressin in endothelial cells of rat pulmonary artery. Anat. Embryol. 183: 129-134, 1991.
20. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature Lond. 357: 336-339, 1992.
21. László, F. A., F. J. László, and D. D. Wied. Pharmacology and clinical perspectives of vasopressin antagonist. Pharmacol. Rev. 43: 73-108, 1991.
22. Morton, J. J., E. C. Beattie, and F. MacPherson. Angiotensin II receptor antagonist losartan has persistent effect on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J. Vasc. Res. 29: 264-269, 1992.
23. 2 receptors in conscious dogs. Am. J. Physiol. 265 (Regulatory Integrative Comp. Physiol. 34): R934-R942, 1993.
24. Oddie, C. J., R. J. Dilley, and A. Bobik. Long-term angiotensin II antagonism in spontaneously hypertensive rats: effect on blood pressure and cardiovascular amplifiers. Clin. Exp. Pharmacol. Physiol. 19: 392-395, 1992.
25. Rapp, J. P. A genetic locus (hyp 2) controlling vascular smooth muscle response in spontaneously hypertensive rats. Hypertension Dallas 4: 459-462, 1982.
26. Schwartz, J., and I. A. Reid. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs. Am. J. Physiol. 244 (Regulatory Integrative Comp. Physiol. 13): R74-R77, 1983.
27. Thibonnier, M., M. E. Soto, J. Menard, J. C. Aldiger, P. Corvol, and P. Milliez. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur. J. Clin. Invest. 11: 449-453, 1981.
28. Undesser, K. P., E. M. Hasser, J. R. Haywood, A. K. Johnson, and V. S. Bishop. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ. Res. 56: 410-417, 1985.
29. Unger, T., P. Rohmeiss, G. Demmert, D. Ganten, R. E. Lang, and F. C. Luft. Differential modulation of baroreceptor reflex by brain and plasma vasopressin. Hypertension Dallas 8, Suppl. II: II-157-II-162, 1986.
30. Veelken, R., L. Danckwart, P. Rohmeiss, and T. Unger. Effects of intravenous AVP on cardiac output, mesenteric hemodynamics and splanchnic nerve activity. Am. J. Physiol. 257 (Heart Circ. Physiol. 26): F658-F664, 1989.
31. Yamamura, Y., H. Ogawa, T. Chihara, K. Hondo, T. Onogawa, S. Nakamura, T. Mori, M. Tominaga, and Y. Yabuuchi. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science Wash. DC 252: 572-574, 1991.
32. 2 receptor antagonist. Br. J. Pharmacol. 105: 787-791, 1992.